May 27, 2023 USPTO approves AliquantumRx Inc.’s patent “Salts and Polymorphs of Cethromycin for the Treatment of Bacterial and Protozoan Disease”

AliquantumRx Inc., a Johns Hopkins FastForward company supported by Maryland Technology Development Corporation (TEDCO) is proud to announce the approval of its patent “Salts and Polymorphs of Cethromycin for the Treatment of Bacterial and Protozoan Disease”.

“The Maryland Innovation Initiative (MII) is glad to have been a part of AliquantumRx Inc.’s early innovation journey,” said Arti Santhanam, PhD, executive director of MII, TEDCO. “The company’s recent patent approval is a huge step forward, and we wish them continued success in their next stages of development.” “We are very excited that the USPTO approved our new salt formulation of cethromycin” said Dr. Sullivan, Chairman of the Board of AliquantumRx Inc. Since the chemical and composition patent of cethromycin expired in 2016, patenting a new Cethromycin polymorph starts an additional 20-year patent term.” “This is a game changer for Aliquantum” added Nik Kaludov, PhD, President of AliquantumRx. Cethromycin has broad spectrum activities against a variety of bacterial and protozoan infectious diseases. This new patent will allow us to pursue indications in addition to malaria for cethromycin, affording multiple shots on goal and further de-risking its commercialization. Additional drug indications exist for drug resistant bacteria, agents of sexually transmitted diseases, bioterror microbes, diarrhea, and atypical respiratory infections. Cethromycin is active against Qualified Infectious Diseases pathogens, which would add 5 years of marketing exclusivity and the company might qualify for various development incentives of the Orphan Drug Act, including tax credits. Last but not least, AliquantumRx Inc. would be eligible for a Neglected Tropical Disease Priority Review Voucher.

Cautionary Note Regarding Forward-Looking Statements

Except for historical information, the matters set forth above may be forward-looking statements that involve risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, such as the failure to meet the conditions imposed by the FDA or other regulators, statements with respect to internal expectations, the competitive environment within the industry, the ability of AliquantumRx to continue to expand its operations, the level of costs incurred in connection with AliquantumRx’s expansion efforts, and economic conditions in the industry. AliquantumRx does not undertake any obligation to update such forward-looking statements.